台灣訂購 BioCoreUSA產品請洽 卓昇有限公司 交貨迅速 品質有保障 電話: 02-2736 7100
BioCoreUSA 是一家專門從事與組織樣本相關的開發、銷售和生物技術服務的公司。 我們的組織庫包含超過 100,000 個石蠟組織塊（超過 15 個解剖系統和 50 個解剖部位），提供可用於研究、常規 IHC 控制和教育的人體、動物組織塊和組織切片。具體而言，組織微陣列包括來自正常組織、癌組織和轉移癌組織的供體塊。 此外，組織微陣列包含蛋白質、RNA 和 DNA 分子，它們為快速分析與疾病診斷、預後和治療相關的分子標誌物提供了高通量工具。我們的一些組織芯片有臨床數據，免疫組化染色結果。稍後將為我們的一些組織陣列添加生存數據。 我們還提供 H&E 高分辨率掃描圖像，讓客戶可以直接在我們公司網站上看到 100x-400x 的顯微鏡圖像。
Services
|
Tissue Array Creation
Histology Services
Image Scanning
Pathology Report
Molecular Histopathology Services
我們提供以下服務以滿足您的組織學和病理學需求：
1. Immunohistochemistry (IHC)
2..Immunofluorescent (IF) stain (single or double antibody staining)
3. Fluorescence in situ hybridization (FISH)
4. mRNA, lncRNA or microRNA In Situ hybridization, including RNAscope® in situ hybridization (ISH) assay
5. In Situ apoptosis (TUNEL) assay
6. In Situ BrdU or EdU cell proliferation assay
7. In Situ autophagy detection assay
Laser Capture Microdissection (LCM) Services
Laser Capture Microdissection (LCM/LMD) Associated Contract Research Project
Laser Capture Microdissection (LCM/LMD) Approach and Advantages
LCM is a contact-free technique that helps minimize contamination and uncover answers that might otherwise be missed using a non-targeted sample due to the small size or homogenized nature of the sample. The laser cutting width is usually less than 1 µm, thus the target cells are not affected by the laser beam. Even live cells are not damaged by the laser cutting and are viable after cutting for cloning and reculturing as appropriate. The laser capture micro-dissection process does not alter or damage the morphology and chemistry of the sample collected, nor the surrounding cells. For this reason, LCM is a useful method of collecting selected cells for DNA, RNA and/or protein analyses. LCM has also been used to isolate cellular structures, such as amyloid plaques. LCM can be performed on frozen and paraffin embedded archival tissues. A variety of tissue samples including blood smears, cytologic preparations, cell cultures and liquors of solid tissue may also be used.
More information please visit https://www.biocoreusa.com
台灣訂購專線請洽: 卓昇有限公司 (02)2736 7100或0800 088 700
我要詢價/訂貨
Name | Category | Description | Cores | Cases |
| AC451 | Skin | Condyloma acuminatum and skin tissue array, 45 cases/45 cores | 45 | 45 |
| B-0011Eso-3b | Esophagus | Esophagus, cardia cancer tissue array with cancer adjacent tissue, including pathology grade, TNM and clinical stage, 50 cases/50 cores, replacing BC001113a | 50 | 50 |
| B-010Bre | Breast | Breast invasive carcinoma of no special type tissue array, including pathology grade, TNM, clinical stage, 10 cases/10 cores | 10 | 10 |
| B-0201Eso-2 | Esophagus | Esophagus cancer with adjacent normal esophagus tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores | 72 | 72 |
| B-0201Eso-2b | Esophagus | Esophagus cancer with adjacent normal esophagus tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores, replacing BC02012a | 72 | 72 |
| B-0301Liv-1 | Liver | Liver cirrhosis and benign tumor tissue array, 63 cases/63 cores | 63 | 63 |
| B-0301Liv-3a | Liver | Hepatocellular carcinoma tissue array, including pathology grade, TNM and clinical stage, 23 cases/63 cores, replacing BS03013 | 63 | 23 |
| B-0311Liv-9e | Liver | Liver cancer with liver tissue array, including pathology grade, TNM and clinical stage, 120 cases/120 cores | 120 | 120 |
| B-03Liv-1c | Liver | Liver cancer tissue array, including pathology grade, TNM and clinical stage, 6 cases/24cores, replacing T031b | 24 | 6 |
| B-03Liv-1d | Liver | Liver cancer tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T031c | 24 | 6 |
| B-03Liv-2c | Liver | Liver tumor with liver tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replacing T032b | 24 | 12 |
| B-03Rat-1 | Rat | Rat normal liver test tissue array, 6 cases/24 cores | 24 | 6 |
| B-0401Lun-7c | Lung | Lung cancer tissue array, including pathology grade, TNM and clinical stage, 48 cases/96 cores | 96 | 48 |
| B-0408Lun-1a | Lung | Lung cancer tissue array with adjacent lung tissue, including pathology grade, TNM and clinical stage, 21 cases/63 cores, replacing BS04081 | 63 | 21 |
| B-04Lun-3a | Lung | Lung cancer with normal lung tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T043 | 24 | 6 |
| B-04Lun-7b | Lung | Non-small cell lung cancer tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T047a | 24 | 6 |
| B-04Lun-a | Lung | PD-L1 tested non-small cell lung cancer tissue array, which is suitable for tumor immunotherapy, including pathology grade, TNM, clinical stage and PD-L1(Sp263) information, 4 cases/4 core, replacing LC04 | 4 | 4 |
| B-04Rat-1 | Rat | Rat normal lung test tissue array, 6 cases/24 cores | 24 | 6 |
| B-05Bre-1 | Breast | Breast cancer tissue array with normal breast tissue, including pathology grade, TNM, clinical stage, 5 cases/5 cores | 5 | 5 |
| B-05Col-3d | Colon | Colon cancer tissue array with normal tissue, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T053c | 24 | 6 |
| B-05Col-4d | Colon | Colon cancer tissue array with normal colon tissue, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replacing T054c | 24 | 12 |
| B-05Col-4e | Colon | Colon cancer tissue array with normal colon tissue, including pathology grade, TNM and clinical stage, 12 cases/ 24 cores, replacing T054d | 24 | 13 |
| B-07Rat-1a | Rat | Rat normal kidney tissue array, 6 cases/24 cores, replacing TR071 | 24 | 6 |
| B-0801Bre-3e | Breast | Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores, replacing BC08013d | 72 | 72 |
| B-08Bre-2a | Breast | Breast cancer tissue array, including pathology grade, TNM and clinical stage, 4 cases/8 cores, replacing BR082 | 8 | 4 |
| B-08Bre-7d | Breast | Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c | 24 | 6 |
| B-1001Lun-1 | Lung | Lung non-small cell carcinoma tissue array with lung tissue, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-1001Lun-2 | Lung | Lung non-small cell carcinoma with lung tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-1001Lun-3 | Lung | Lung adenocarcinoma with matched adjacent normal lung tissue array, including pathology grade, TNM, clinical stage, 52 cases/100 cores | 100 | 52 |
| B-1001Lun-4 | Lung | Lung adenocarcinoma tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-1001Lun-5 | Lung | Lung squamous cell carcinoma tissue array, including pathology grade, TNM, clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Bal-1 | Baldder | Bladder tumor tissue array, including TNM and clinical stage, 25 cases/100 cores | 100 | 25 |
| B-100Bal-2a | Baldder | Bladder cancer array with cancer adjacent tissue, including TNM and pathology grade, 50 cases/100 cores | 100 | 50 |
| B-100Bal-3 | Baldder | Bladder cancer tissue array with bladder tissue, including TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Bra-2 | Brain | Brain tumor and normal tissue array, 50 cases/100 cores | 100 | 50 |
| B-100Bre-1 | Breast | Breast cancer and breast tissue array, with metastatic carcinoma, including pathology grade, TNM and clinical stage, 96 cases/100 cores | 100 | 96 |
| B-100Bre-3b | Breast | Multiple types breast cancer tissue array, including pathology grade, TNM and clinical stage, 47 cases/101 cores, replacing BR1003a | 101 | 47 |
| B-100Bre-9 | Breast | Breast cancer tissue array with normal tissue, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Col-2c | Colon | Colorectal carcinoma and matched colon tissue array (2010 WHO classification), with lymph node metastasis carcinoma, including pathology grade, TNM and clinical stage (AJCC 7th edition), 64 cases/100 cores, replacing CO1002b | 100 | 64 |
| B-100Col-3 | Colon | Colon cancer with metastatic carcinoma tissue array, including pathology grade, 100 cases/100 cores | 100 | 100 |
| B-100Col-5 | Colon | Colon cancer and adenoma tissue array with normal tissue, including pathology grade, TNM and clinical stage, 100 cases/100 cores | 100 | 100 |
| B-100End-1 | Endometrium | Endometrial cancer tissue array for antibody screening, including pathology grade, TNM and clinical stage, 25 cases/100 cores | 100 | 25 |
| B-100Eso-2 | Esophagus | Esophagus cancer tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Gal-1 | Liver | Gallbladder cancer tissue array with adjacent normal tissue, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Kid-2 | Kidney | Kidney cancer tissue array with adjacent normal tissue, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Liv-2 | Liver | Liver cancer with liver tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Lun-5a | Lung | Lung cancer progression tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores, replacing LC1005 | 100 | 100 |
| B-100-Mel-2a | Melanoma | Malignant melanoma tissue array with normal skin tissue as control, including pathology grade, TNM and clinical stage, 50 cases/100 cores, replacing ME1002 | 100 | 50 |
| B-100Mel-2c | Melanoma | Malignant melanoma with skin tissue array, including TNM and clinical stage, 50 cases/100 cores, replacing ME1002b | 100 | 50 |
| B-100Mel-4i | Melanoma | Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage, 100 cases/100 cores, replacing ME1004h | 100 | 100 |
| B-100Mou-1 | Mouse | Mouse normal kindey tissue array, 100 cases/100 cores | 100 | 100 |
| B-100Mou-2 | Mouse | Mouse brain tissue array, 100 cases/ 100 cores, replacing MO17011 | 100 | 100 |
| B-100Ova-2 | Ovary | Ovary tumor tissue array, 100 cases/100 cores | 100 | 100 |
| B-100Ova-5c | Ovary | Ovary disease spectrum (ovary cancer progression) tissue array (2014 WHO classification), including pathology grade, TNM and clinical stage, 100 cases/100 cores, replacing OV1005b | 100 | 100 |
| B-100Ova-6 | Ovary | Ovary carcinoma tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores | 100 | 100 |
| B-100Pan-1 | Appendix | Vermiform appendix disease spectrum (vermiform appendix cancer progression) tissue array, including pathology grade, 50 cases/100 cores | 100 | 50 |
| B-100Pan-1b | Pancreas | Pancreatic cancer tissue array, with adjacent normal pancreas tissue and normal pancreas tissue, including pathology grade, TNM and clinical stage, 50 cases/100 cores, replacing PA1001a | 100 | 50 |
| B-100Pan-1c | Pancreas | Pancreas cancer tissue array with pancreas tissue, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Pan-4 | Pancreas | Pancreas cancer tissue array with pancreatitis and pancreas tissue, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Spl-1 | Spleen | Spleen disease spectrum (splenic cancer progression) tissue array, 50 cases/100 cores | 100 | 50 |
| B-100Spl-2 | Spleen | Spleen lymphoma tissue array with matched cancer adjacent spleen tissue, 50 cases/100 cores | 100 | 50 |
| B-100Sto-1b | Stomach | Stomach disease spectrum (stomach cancer progression) tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores, replacing ST1001a | 100 | 100 |
| B-100Sto-3a | Stomach | Stomach cancer tissue array for antibody screening, including pathology grade, TNM and clinical stage, 50 cases/100 cores, replacing ST1003 | 100 | 50 |
| B-100Sto-6 | Stomach | Stomach cancer tissue array with matched stomach tissue, including pathology grade, TNM and clinical stage, 50 cases/100 cores | 100 | 50 |
| B-100Ton-2a | Nasopharynx-Larynx | Tonsil disease spectrum tissue array, 50 cases/100 cores | 100 | 50 |
| B-102Bre-1 | Breast | Multiple types breast cancer tissue array with adjacent normal tissue, including pathology grade, TNM and clinical stage, 102 cases/102 cores | 102 | 102 |
| B-102End-1 | Endometrium | Endometrial cancer tissue array, including pathology grade, TNM and clinical stage, 102 cases/102 cores | 102 | 102 |
| B-102End-1b | Endometrium | Endometrium cancer with endometrium tissue array, including pathology grade, TNM and clinical stage, 102 cases/102 cores, replacing EM1021a | 102 | 102 |
| B-102Eso-1 | Esophagus | Esophagus cancer tissue array, including pathology grade, TNM and clinical stage, 102 cases/102 cores | 102 | 102 |
| B-102Eso-2 | Esophagus | Different stages of esophagus cancer and esophagus tissue array, including pathology grade, TNM and clinical stage, 102 cases/102 cores | 102 | 102 |
| B-102Int-1 | Intestine | Small intestine carcinoma tissue array with matched small intestine tissue, including pathology grade, TNM and clinical stage, 34 cases/102 cores | 102 | 34 |
| B-102Sto-1 | Stomach | Stomach cancer with normal tissue array, including pathology grade, TNM and clinical stage, 102 cases/102 cores | 102 | 102 |
| B-104Lun-1 | Lung | Lung cancer tissue array with normal tissue, including pathology grade, TNM, clinical stage , 104 cases/104 cores | 104 | 104 |
| B-105Liv-1 | Liver | Liver cholangiocarcinoma tissue array with matched adjacent normal or cancer adjacent liver tissue, including pathology grade, TNM and clinical stage, 35 cases/105 cores | 105 | 35 |
| B-110Pro-1 | Prostate | Prostate cancer with hyperplasia tissue array, including TNM, clinical stage, Gleason grade and Gleason scores, 110 cases/110 cores | 110 | 110 |
| B-110Sto-1 | Stomach | Stomach cancer tissue array with adjacent normal tissue, including pathology grade, TNM and clinical stage, 110 cases/110 cores | 110 | 110 |
| B-112Bre-1 | Breast | Triple negative breast cancer with normal tissue array, including pathology grade, TNM, clinical stage, 112 cases/112 cores | 112 | 112 |
| B-114Bre-1 | Breast | Breast cancer tissue array, including pathology grade, TNM and clinical stage, 114 cases/114 cores | 114 | 114 |
| B-120Bre-1 | Breast | Breast cancer tissue array (most of triple negative), including pathology grade, TNM, clinical stage, 120 cases/120 cores | 120 | 120 |
| B-120Car-1 | Stomach | Cardia cancer tissue array with matched adjacent normal or cancer adjacent tissue, including pathology grade, TNM and clinical stage, 60 cases/120 cores | 120 | 60 |
| Cat No. | Sex | Age | Organ/Anatomic Site | TNM | Stage | Grade | Pathology diagnosis | Operation Findings | Type |
| Dca2050005 | M | 48 | Esophagogastric junction | T3N0M0 | IIA | 3 | Adenocarcinoma | Partial pro*imal stomach were resected, with the total volume of 10*5*5cm and the tumor volume of 3*3*2cm. | FFPE |
| Dca2050006 | F | 72 | Esophagogastric junction | T3N1M0 | IIB | 3 | Adenocarcinoma | Partial pro*imal stomach were resected, with the total volume of 12*8*3cm and the tumor volume of 4*4*2cm. | FFPE |
| Dca2050007 | F | 51 | Esophagogastric junction | T3N0M0 | IIA | 3 | Adenocarcinoma | Partial pro*imal stomach were resected, with the total volume of 12*10*4cm and the tumor volume of 5*3*2cm. | FFPE |
| Dca2050008 | M | 54 | Esophagogastric junction | T3N2M0 | IIIA | 2 | Adenocarcinoma | Partial pro*imal stomach were resected, with the total volume of 10*6*3cm and the tumor volume of 3*2*2cm. | FFPE |
| Dca2050009 | M | 51 | Esophagogastric junction | T3N3aM0 | IIIB | 3 | Adenocarcinoma | Partial stomach were resected, with the total volume of 8*6*3cm and the tumor volume of 2*2*2cm. | FFPE |
| Dca2050010 | M | 51 | Esophagogastric junction | T3N3aM0 | IIIB | 3 | Adenosquamous carcinoma | Partial stomach were resected, with the total volume of 8*6*4cm and the tumor volume of 2*2*2cm. | FFPE |
| Dca2050011 | M | 60 | Stomach | T3N0M0 | IIA | 2 | Squamous cell carcinoma | Partial pro*imal stomach were resected, with the total volume of 12*8*4cm and the tumor volume of 5*5*4cm. | FFPE |
| Dca2050012 | M | 57 | Esophagogastric junction | T4bN2M0 | IIIB | 4 | NEC(small+cell+carcinoma) | FFPE | |
| Dca2050013 | M | 62 | Stomach | T3N3aM0 | IIIB | 2 | Squamous cell carcinoma | FFPE | |
| Dca2050014 | F | 50 | Esophagogastric junction | T3N2M0 | IIIA | 3 | Adenocarcinoma | FFPE | |
| Dca2050015 | F | 60 | Stomach | T4aN3bM0 | IIIC | 3 | Adenocarcinoma | FFPE | |
| Dca2050016 | M | 60 | Esophagogastric junction | T3N3aM0 | IIIB | 3 | Adenocarcinoma | FFPE | |
| Dca2050017 | M | 73 | Esophagogastric junction | T3N2M0 | IIIA | 4 | NEC | FFPE | |
| Dca2050018 | M | 70 | Esophagogastric junction | T2N0M0 | IB | 3 | Adenocarcinoma | FFPE | |
| Dca2050019 | M | 67 | Esophagogastric junction | T3N0M0 | IIA | 1 | Adenocarcinoma | FFPE | |
| Dca2050020 | M | 76 | Esophagogastric junction | T3N1M0 | IIB | 2 | Adenocarcinoma | Partial pro*imal stomach were resected, with the total volume of 9*5*4cm and the tumor volume of 3.5*2.5*2cm. | FFPE |
| Dca2050021 | M | 71 | Esophagogastric junction | T3N1M0 | IIB | 2 | Adenocarcinoma | Ulcerative mass were resected, with the total volume o 7*3*2.5. | FFPE |
| Dca2050022 | M | 72 | Esophagogastric junction | T3N0M0 | IIA | 2 | Adenocarcinoma | Partial pro*imal stomach were resected, with the total volume of 10*8*6cm and the tumor volume of 4*3*2cm. | FFPE |
| Dca2050023 | M | 70 | Esophagogastric junction | T4aN0M0 | IIB | 3 | Adenocarcinoma | Partial pro*imal stomach were resected, with the total volume of 8*8*3cm and the tumor volume of 3*2*1cm. | FFPE |
| Dca2050024 | F | 61 | Esophagogastric junction | T3N0M0 | IIA | 2 | Adenosquamous carcinoma | The tumour in the esophagogastric junction were resected, with the total volume of 8*4*2cm. | FFPE |
| Dca2050025 | F | 49 | Esophagogastric junction | T3N0M0 | IIA | 3 | Mucinous adenocarcinoma | The tumour in the esophagogastric junction were resected, with the total volume of 5*3*3cm. | FFPE |
| Dca2050026 | M | 51 | Esophagogastric junction | T3N0M0 | IIA | 2 | Adenocarcinoma | Ulcerative mass were resected, with the total volume of 4*4*2cm. | FFPE |
| Dca2050027 | M | 62 | Esophagogastric junction | T3N0M0 | IIA | 2 | Mucinous adenocarcinoma | Partial pro*imal stomach were resected, with the total volume of 15*13*2cm and the tumor volume of 5*4*2cm. | FFPE |
| Dca2050028 | M | 68 | Esophagogastric junction | T3N0M0 | IIA | 2 | NET G2 | Partial pro*imal stomach were resected, with the tumor volume of 5*5*4cm. | FFPE |
| Dca2050029 | M | 48 | Esophagogastric junction | T3N2M0 | IIIA | 3 | Adenocarcinoma | The tumour in the esophagogastric junction were resected, with the total volume of 5*5*3cm. | FFPE |
| Dco205230 | M | 30 | Colon | T2N0M0 | I | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 6.5*4.5*1cm. | FFPE |
| Dco205231 | M | 58 | Colon | T3N2bM0 | IIIC | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 6.5*4.5*1.5cm. | FFPE |
| Dco205232 | F | 55 | Colon | T2N0M0 | I | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 4.5*4*0.5cm. | FFPE |
| Dco205233 | F | 76 | Sigmoid colon | T3N0M0 | IIA | 1 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 4*2*2cm. | FFPE |
| Dco205234 | F | 53 | Sigmoid colon | T3N0M0 | IIA | 3 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 3*2*1.5cm. | FFPE |
| Dco205235 | F | 44 | Colon | T3N0M0 | IIA | 3 | Mucinous adenocarcinoma | Partial colon were resected, with the tumor volume of 3*2*2cm. | FFPE |
| Dco205236 | M | 60 | Colon | T2N0M0 | I | 1 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 3*2*2cm. | FFPE |
| Dco205237 | F | 65 | Colon | T3N0M0 | IIA | 1 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 3*2*1cm. | FFPE |
| Dco205238 | M | 64 | Colon | T2N0M0 | I | 1 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 3*3*2cm. | FFPE |
| Dco205239 | M | 58 | Colon | T3N0M0 | IIA | 3 | Adenocarcinoma | Partial colon were resected, with the tumor volume of4*3.5*2cm. | FFPE |
| Dco205240 | F | 60 | Colon | T3N1bM0 | IIIB | 3 | Mucinous adenocarcinoma | Partial colon were resected, with the tumor volume of 4*2*1cm. | FFPE |
| Dco205241 | M | 58 | Colon | T3N2aM0 | IIIC | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 3*2.5*2cm. | FFPE |
| Dco205242 | M | 38 | Colon | T3N2bM0 | IIIC | 2 | Adenocarcinoma | Partial colon were resected, with the total length of 18cm and the tumor volume of 4*4*2cm. | FFPE |
| Dco205243 | F | 38 | Colon | T3N1M0 | IIIB | 1月2日 | Adenocarcinoma | Partial colon were resected, with the total length of 16cm and the tumor volume of 3*3*2cm. | FFPE |
| Dco205244 | F | 47 | Colon | T3N0M0 | IIA | 2 | Squamous cell carcinoma | Partial colon were resected, with the tumor volume of 5*3*1.5cm. | FFPE |
| Dco205245 | M | 65 | Colon | T3N2bM0 | IIIC | 2月3日 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 5*4.5*1cm. | FFPE |
| Dco205246 | M | 50 | Colon | T3N2bM0 | IIIC | 2月3日 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 5*4.5*0.5cm. | FFPE |
| Dco205247 | F | 53 | Colon | T3N2aM0 | IIIB | 3 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 6.5*5*1cm. | FFPE |
| Dco205248 | M | 60 | Colon | T2N2aM0 | IIIB | 3 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 5*5*0.6cm. | FFPE |
| Dco205249 | F | 47 | Colon | T3N2aM0 | IIIB | 3 | Neuroendocrine carcinoma | Partial colon were resected, with the tumor volume of 5*4.5*0.5cm. | FFPE |
| Dco205250 | F | 48 | Colon | T3N0M0 | IIA | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 4*2*2cm. | FFPE |
| Dco205251 | M | 37 | Colon | T3N0M0 | IIA | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 5*4.5*0.5cm. | FFPE |
| Dco205252 | F | 44 | Colon | T3N1M0 | IIIB | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 4*4*1cm. | FFPE |
| Dco205253 | M | 52 | Colon | T3N2aM0 | IIIB | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 3*2*0,5cm. | FFPE |
| Dco205254 | F | 47 | Ascending colon | T3N0M0 | IIA | 3 | Neuroendocrine carcinoma | Partial colon were resected, with the tumor volume of 10*8*2cm. | FFPE |
| Dco205255 | M | 58 | Colon | T3N1bM0 | IIIB | 1月2日 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 2.5*2*2cm. | FFPE |
| Dco205256 | F | 48 | Colon | T3N0M1 | IV | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 6*3.8*2.7cm. | FFPE |
| Dco205257 | F | 64 | Ascending colon | T4aN0M0 | IIB | 1月2日 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 5.5*5*2.5cm. | FFPE |
| Dco205258 | M | 46 | Ascending colon | T4aN1bM0 | IIIb | 2 | Squamous cell carcinoma | Partial colon were resected, with the tumor volume of 6*4*3cm. | FFPE |
| Dco205259 | M | 46 | Ascending colon | T3N1M0 | IIIB | 3 | Neuroendocrine carcinoma | Partial colon were resected, with the tumor volume of 7*4*3cm. | FFPE |
| Dco205260 | M | 56 | Ascending colon | T4aN2bM0 | IIIC | 1月2日 | Squamous cell carcinoma | Partial colon were resected, with the tumor volume of 7.5*6*4cm. | FFPE |
| Dco205261 | M | 71 | Sigmoid colon | T4aN0M0 | IIB | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 5*4*3cm. | FFPE |
| Dco205262 | M | 63 | Ascending colon | T3N0M0 | IIB | 2 | Adenocarcinoma | Partial colon were resected, with the tumor volume of 6*6*5cm. | FFPE |
| Des201001 | M | 62 | Esophagus | T2N0M0 | IB | 1 | Esophageal squamous cell carcinoma | Partial esophagus were resected, with the total length of 9cm and the tumor volume of 2*2*1cm. | FFPE |
| Des201002 | M | 55 | Esophagus | T3N0M0 | IIA | 1 | Esophageal squamous cell carcinoma | Partial esophagus were resected, with the total length of 8cm and the tumor volume of 2.5*1*0.5cm. | FFPE |
RARE CASES
| Odontogenic tumors | Ameloblastoma | FFPE | Enquiry |
| Odontogenic tumors | calcifying epithelial odontogenic tumor | FFPE | Enquiry |
| Soft tissue tumor | Atypical lipomatous tumor / well differentiated liposarcoma | FFPE | Enquiry |
| Soft tissue tumor | Desmoid type fibromatosis | FFPE | Enquiry |
| Soft tissue tumor | Low grade myofibroblastic sarcoma | FFPE | Enquiry |
| Soft tissue tumor | Giant cell tumor of tendon sheath | FFPE | Enquiry |
| Tumor of the salivary gland | Acinar cell carcinoma | FFPE | Enquiry |
| Tumor of the salivary gland | Carcinoma ex pleomorphic adenoma | FFPE | Enquiry |
| Tumor of the salivary gland | Basal cell adenoma | FFPE | Enquiry |
| Tumor of the salivary gland | Warthin tumour | FFPE | Enquiry |
| Tumor of the salivary gland | Oncocytoma | FFPE | Enquiry |
| Tumors of gynecologic | Tumors of gynecologic | FFPE | Enquiry |
| Tumors of the bladder | Papillary urothelial neoplasm of low malignant potential | FFPE | Enquiry |
| Tumors of the bladder | small cell carcinoma | FFPE | Enquiry |
| Tumors of the bladder | Carcinoid | FFPE | Enquiry |
| Tumors of the breast | Plasma cell mastitis | FFPE | Enquiry |
| Tumors of the breast | granulomatous mastitis | FFPE | Enquiry |
| Tumors of the breast | Sclerosing adenosis | FFPE | Enquiry |
| Tumors of the breast | Atypical ductal hyperplasia | FFPE | Enquiry |
| Tumors of the breast | Ductal carcinoma in situ | FFPE | Enquiry |
| Tumors of the breast | Mixed type carcinoma | FFPE | Enquiry |
| Tumors of the breast | Tubular carcinoma | FFPE | Enquiry |
| Tumors of the breast | Invasive micropapillary carcinoma | FFPE | Enquiry |
| Tumors of the breast | Apocrine adenocarcinoma | FFPE | Enquiry |
| Tumors of the breast | Metaplastic carcinoma | FFPE | Enquiry |
| Tumors of the breast | Secretory carcinoma | FFPE | Enquiry |
| Tumors of the breast | Inflammatory carcinoma | FFPE | Enquiry |
| Tumors of the breast | bilateral breast cancer | FFPE | Enquiry |
| Tumors of the breast | Angiosarcoma | FFPE | Enquiry |
| Tumors of the breast | Phyllodes tumors | FFPE | Enquiry |
| Tumors of the kidney | multilocular cystic renal cell carcinoma | FFPE | Enquiry |
| Tumors of the kidney | chromophobe renal cell carcinoma | FFPE | Enquiry |
| Tumors of the kidney | renal cell carcinoma associated with Xp11.2 translocation / TFE3 gene fusions | FFPE | Enquiry |
| Tumors of the kidney | Papillary adenoma of the kidney | FFPE | Enquiry |
| Tumors of the kidney | Oncocytoma | FFPE | Enquiry |
| Tumors of the kidney | Metanephric adenoma | FFPE | Enquiry |
| Tumors of the kidney | Nephroblastoma | FFPE | Enquiry |
| Tumors of the kidney | Rhabdoid tumor | FFPE | Enquiry |
| Tumors of the kidney | Epithelioid angiomyolipoma | FFPE | Enquiry |
| Tumors of the ovary | Serous borderline tumor | FFPE | Enquiry |
| Tumors of the ovary | Mucinous borderline tumor | FFPE | Enquiry |
| Tumors of the ovary | simultaneous endometrioid carcinoma of the ovary and uterus | FFPE | Enquiry |
| Tumors of the ovary | Clear cell adenocarcinoma | FFPE | Enquiry |
| Tumors of the ovary | Granulosa cell tumor group | FFPE | Enquiry |
| Tumors of the ovary | juvenile granulose cell tumor | FFPE | Enquiry |
| Tumors of the ovary | Immature teratoma | FFPE | Enquiry |
| Tumors of the ovary | Struma ovarii | FFPE | Enquiry |
| Tumors of the ovary | Carcinoid | FFPE | Enquiry |
| Tumors of the ovary | Small cell carcinoma, hypercalcemia type | FFPE | Enquiry |
| Tumors of the penis | Verrucous carcinoma | FFPE | Enquiry |
| Tumors of the penis | Sarcomatoid carcinoma | FFPE | Enquiry |
| Tumors of the prostate | Prostatic intraepithelial neoplasm | FFPE | Enquiry |
| Tumors of the prostate | Ductal adenocarcinoma | FFPE | Enquiry |
| Tumors of the prostate | Neuroendocrine tumors | FFPE | Enquiry |
| Tumors of the testis | Teratoma with somatic-type malignancy | FFPE | Enquiry |
| Tumors of the testis | Choriocarcinoma | FFPE | Enquiry |
| Tumors of the testis | Granulosa cell tumor group | FFPE | Enquiry |
| Tumors of the testis | Adenomatoid tumor | FFPE | Enquiry |
| Tumors of the Urinary System | FFPE | Enquiry | |
| Tumors of the uterine cervix | Cervical intraepithelial neoplasm | FFPE | Enquiry |
| Tumors of the uterine cervix | Slightly deviated adenocarcinoma | FFPE | Enquiry |
| Tumors of the uterine cervix | sarcoma botryoided | FFPE | Enquiry |
| Tumors of the uterine corpus | Endometrial stromal sarcoma, low grade | FFPE | Enquiry |
| Tumors of the uterine corpus | Endometrial stromal nodule | FFPE | Enquiry |
| Tumors of the uterine corpus | Carcinosarcoma | FFPE | Enquiry |
| Tumors of the uterine corpus | Choriocarcinoma | FFPE | Enquiry |
| Tumors of the uterine corpus | hydatidiform mole | FFPE | Enquiry |
| Tumors of the uterine corpus | Invasive hydatidiform mole | FFPE | Enquiry |
| Tumors of the Vaginal and vulvar | Malignant melanoma | FFPE | Enquiry |
| Tumors of the Vaginal and vulvar | Head and Neck Tumours | FFPE | Enquiry |
| Tumors of the Vaginal and vulvar | Lymphoepithelial carcinoma | FFPE | Enquiry |
| Tumors of the Vaginal and vulvar | Myxoma | FFPE | Enquiry |
| Tumors of the Vaginal and vulvar | Olfactory neuroblastoma | FFPE | Enquiry |
| Tumors of the Vaginal and vulvar | Undifferentiated carcinoma | FFPE | Enquiry |
| Tumors of the Vaginal and vulvar | Keratoacanthoma | FFPE | Enquiry |
| Tumours of the ear | Endolymphatic sac tumor | FFPE | Enquiry |